Research output per year
Research output per year
Search results
-
2022
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial
CALM Study Group, Nov 2022, In: The Lancet Haematology. 9, 11, p. e833-e843Research output: Contribution to journal › Article › peer-review
57 Citations (Scopus) -
2021
Chimeric antigen receptor-modified human regulatory T cells that constitutively express IL-10 maintain their phenotype and are potently suppressive
Mohseni, Y. R., Saleem, A., Tung, S. L., Dudreuilh, C., Lang, C., Peng, Q., Volpe, A., Adigbli, G., Cross, A., Hester, J., Farzaneh, F., Scotta, C., Lechler, R. I., Issa, F., Fruhwirth, G. O. & Lombardi, G., Oct 2021, In: European Journal of Immunology. 51, 10, p. 2522-2530 9 p.Research output: Contribution to journal › Article › peer-review
Open Access22 Citations (Scopus) -
2020
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
UCART19 Group, 12 Dec 2020, In: The Lancet. 396, 10266, p. 1885-1894 10 p.Research output: Contribution to journal › Article › peer-review
232 Citations (Scopus) -
Non-invasive Reporter Gene Imaging of Cell Therapies, including T Cells and Stem Cells
Ashmore-Harris, C., Iafrate, M., Saleem, A. & Fruhwirth, G. O., 3 Jun 2020, In: Molecular Therapy. 28, 6, p. 1392-1416 25 p., 10.1016/j.ymthe.2020.03.016.Research output: Contribution to journal › Review article › peer-review
Open AccessFile49 Citations (Scopus)168 Downloads (Pure)